Britain's state health service has advised against paying for Pfizer's inhaled insulin Exubera, saying that the therapy isn't worth the added cost. Pfizer called the decision "perverse and short-sighted." Article [1]
Links:
[1] http://money.cnn.com/2006/04/18/news/companies/pfizer_exubera.reut/